Gozetotide
A targeted radiopharmaceutical agent used in the diagnosis and treatment of certain cancers, including prostate and breast cancer. It binds to specific proteins overexpressed on cancer cells, allowing for precise imaging or delivery of radiation.
Moleküler Ağırlık
947,0000 g/mol
LogP
-3,90
TPSA
370,00 Ų
Lipinski RO5
Başarısız
Terapötik Alanlar
Etki Mekanizması
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
2D Yapı
Cite this structure
Embed this structure
SMILES
O=C(O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)O)c1
InChI
InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1
Molecular Formula
C44H62N6O17
HBD / HBA
12 / 19
Döndürülebilir Bağlar
35
Ağır Atomlar
67
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A targeted radiopharmaceutical agent used in the diagnosis and treatment of certain cancers, including prostate and breast cancer. It binds to specific proteins overexpressed on cancer cells, allowing for precise imaging or delivery of radiation.
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
Yes, Gozetotide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3578202. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60143283. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gozetotide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gozetotide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gozetotide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gozetotide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gozetotide"></drugfyi-drug>